Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 3

2(25.0%)

N/A

1(12.5%)

Phase 4

1(12.5%)

8Total

Phase 2(4)

Phase 3(2)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04588285Phase 2Recruiting

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

Role: collaborator

NCT05284266Not ApplicableActive Not Recruiting

The National Lipedema Study

Role: collaborator

NCT06878066Phase 3Recruiting

Thrombolysis in Factor Xa-inhibitors Trial

Role: collaborator

NCT03904173Active Not Recruiting

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

Role: collaborator

NCT03326791Phase 2Active Not Recruiting

Aspirin in Colorectal Cancer Liver Metastases

Role: collaborator

NCT05448547Phase 3Recruiting

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

Role: collaborator

NCT06853743Phase 2Recruiting

The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease

Role: collaborator

NCT03760588Phase 2Completed

Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Role: collaborator

NCT03446534Phase 4Unknown

The Norwegian Antibiotics for Pneumonia in Children Study

Role: collaborator

All 9 trials loaded